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expression was an independent predictive poor prognostic 
factor in patients with PDAC.
Conclusions PD-L1 expression appears to be an important 
prognostic factor in patients with PDAC who underwent 
surgical resection.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a lethal dis-
ease with a poor prognosis; it is the fourth leading cause of 
cancer-related deaths in Japan and the fourth most common 
malignancy in the USA [1, 2]. At the time of PDAC diag-
nosis, less than 20% of the tumors are resectable, and the 
actual 5-year survival rate is reported to range from 15 to 
25% [3]. Current clinical treatments for PDAC have limited 
efficacy; thus, improved treatment strategies are required to 
prolong patient survival.
Expression of programmed death-1 (PD-1) is signifi-
cantly upregulated on activated cancer-specific T cells. 
The PD-1 receptor attaches to its ligand PD-L1, which is 
expressed by tumor cells and infiltrating immune cells. 
The interaction of PD-1 and PD-L1 inhibits T-cell activa-
tion and promotes tumor immune escape [4–7]. The escape 
mechanism acquired by tumor cells to avoid immune 
recognition and destruction is a major contributor to the 
limitations of the therapeutic efficacy. However, recently 
developed therapeutic antibodies against PD1/PD-L1 show 
promising clinical results for several tumors, such as mela-
noma, renal cancer, and non-small cell lung cancer [8].
Although the efficacy of PD-1/PD-L1 antibody therapy 
should be correlated with PD-L1 protein expression in 
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Background Pancreatic ductal adenocarcinoma (PDAC) 
has an extremely poor prognosis. For the development of 
more effective immunotherapies, it is first necessary to 
elucidate the immunological escape mechanisms. In this 
study, we applied our recently developed highly sensitive 
immunostaining method employing fluorescent phosphor-
integrated dot (PID) nanoparticles to evaluate the preva-
lence of programmed death ligand 1 (PD-L1) in patients 
with PDAC.
Methods This study included 42 patients with PDAC who 
underwent pancreatectomy. We evaluated PD-L1 expres-
sion in these patients using PID staining and correlated 
PD-L1 expression level with each patient’s clinico-patho-
logical features.
Results PD-L1 expression was detected in 61.9% (26/42) 
of the patients with PDAC by PID staining. There was a 
significant difference in overall survival between PD-
L1-positive and PD-L1-negative patients [hazard ratio 
(HR) 2.07, 95% confidence interval (CI) 1.00–4.54; 
P = 0.049]. Among CD8+-tumor-infiltrating lymphocyte-
positive cases, the overall survival of PD-L1-positive 
patients was significantly poorer than that of PD-L1-neg-
ative patients (HR 3.84, 95% CI 1.59–10.35; P = 0.003). 
Univariate and multivariate analyses indicated that PD-L1 
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tumor cells, approximately 10–40% of PD-L1 immuno-
negative cases also respond to anti-PD-1/PD-L1 therapy 
[9–11]. This contradiction may be caused by the perfor-
mance of the PD-L1 immunostaining assay which is based 
on the color intensity visualized using the chromogen 
dye diaminobenzidine (DAB). We recently developed an 
immunohistochemistry method using fluorescence-emit-
ting phosphor-integrated dot (PID) nanoparticles as a fluo-
rescent dye. PID shows a higher luminance and dynamic 
range than those of conventional fluorescent dyes and DAB 
[12]. Specifically, the fluorescence intensity of the PID par-
ticles was found to be approximately 100-fold higher than 
that of a conventional fluorescent dye. Also, the ratio of 
particle to antibody binding is 1:1. Thus, this technique is 
highly sensitive as well as quantitative as compared to the 
conventional DAB-based method.
The aim of the study reported here was to evaluate the 
expression of PD-L1 in patients with PDAC by immu-
nostaining using PID technology and to compare the results 
with those obtained after conventional DAB staining.
Materials and methods
Patients and samples
This study included 42 patients with PDAC, of whom 31 
underwent pancreaticoduodenectomy and 11 underwent 
distal pancreatectomy at the Department of Surgery at Kan-
sai Medical University Hospital (Osaka, Japan) between 
May 2001 and December 2007. All patients had histologi-
cally confirmed PDAC. The tumors were classified accord-
ing to the TNM classification [13]. The clinical parameters 
of all patients were collected from a prospectively main-
tained institutional PDAC database.
Surgically resected specimens were fixed in formalin 
and embedded in paraffin; and serial sections cut from 
the embedded specimens were stained with hematoxylin 
and eosin for histological evaluation. The most repre-
sentative tumor areas were sampled for the tissue micro-
array using 2-mm-diameter samples (Azumaya, Tokyo, 
Japan).
This study was conducted in accordance with the Decla-
ration of Helsinki, and the study protocol was approved by 
the institutional review board of our hospital (Protocol no. 
H151043 and 27-14).
Immunohistochemistry
Four-micrometer-thick sections were deparaffinized 
using routine procedures. Endogenous peroxidase activ-
ity in the deparaffinized sections was blocked by treat-
ing the sections with 3% hydrogen peroxide treatment 
for 15 min, followed by washing in deionized water 
for 2–3 min. The sections were subsequently boiled in 
10 mM sodium citrate buffer for 10 min at 121 °C, then 
allowed to cool at room temperature for 40 min, followed 
by rinsing with deionized water and washing with phos-
phate-buffered saline for 5 min.
Measurement of the fluorescence properties of PID
The sections were incubated with the primary antibody 
toward PD-L1 (E1L3N, 1:1000, Cell Signaling Technol-
ogy, Danvers, MA). Sections were incubated with 2 μg/mL 
biotinylated anti-rabbit antibody (LO-RG-1) for 30 min and 
then with PID-conjugated streptavidin (0.06 nM) for 2 h, 
both at room temperature. The sections were then irradiated 
at 580 nm, and the fluorescence intensities were measured 
using a BX53 fluorescence microscope (Olympus, Tokyo, 
Japan); images were acquired with a DP73 CCD camera 
(Olympus) (Fig. 1). The number of PID particles per cell 
was measured with an automated PID Analyzer (Konica 
Minolta, Tokyo, Japan). The number of PD-L1 particles 
was evaluated only on the tumor cells. Five fields at 400× 
magnification were selected randomly, and the number of 
PD-L1 particles on each tumor cell was counted and the 
average number of particles per cell then calculated for 
each field. The highest value among the five fields was 
determined to be the PID staining value. The negative con-
trol was prepared with PID staining but without the pri-
mary antibody.
Measurement of DAB intensity
The sections were incubated with the primary antibody 
toward PD-L1 (E1L3N, 1:200, Cell Signaling Technol-
ogy) diluted in antibody diluent (Signal Stain Antibody 
Diluent #8112; Cell Signaling Technology). The sections 
were treated with peroxidase-labeled secondary antibody 
(EnVision/HRP system; DAKO, Carpinteria, CA) after 
linker reagent treatment for 15 min. The sections were 
then rinsed in the buffer and immersed in DAB to observe 
color development.
For the DAB-naked eye evaluation, three observers 
(S.Y., H.R., K.T.) assessed the immunostaining results in a 
blinded manner without knowledge of the clinical or his-
topathological diagnoses. Intensity was graded on a 3-tier 
scale (1+, negative to weak; 2+, moderate; 3+, strong). 
The percentage of staining was recorded, and a semi-
quantitative (H-score) approach [14] was used for analysis. 
PD-L1 expression scores were calculated (from 0 to 300) 
by multiplying the percentage of the stained tumor area by 
the staining intensity score.
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Double staining of PD‑L1 using the PID method and of 
CD8+ lymphocytes using the DAB method
Double staining, i.e., DAB staining for CD8+ lympho-
cytes and PD-L1 staining with the PID method, was 
performed to count the tumor infiltrating lymphocytes 
(TILs) (primary antibody for PD-L1: E1L3N, 1:100; pri-
mary antibody for CD8: C8/114B, 1:250; DAKO; sec-
ondary antibody: EnVision/HRP system) (Fig. 2).
The correlations between PD-L1 expression, overall 
survival, and clinico-pathological data were evaluated.
Fig. 1  Immunohistochemistry 
of pancreatic ductal adenocar-
cinoma tissue using phosphor-
integrated dot (PID) staining. 
Red spots on tumor cells 
indicate PID particles
Fig. 2  Immunohistochemical 
double staining for programmed 
death ligand 1 (PD-L1) on 
tumor cells and CD8+ lympho-
cytes. PID staining was used for 
PD-L1 detection, and diamin-
obenzidine (DAB) staining was 
used for CD8+ lymphocytes. 
The number of PID particles 
measured by the automated PID 
analyzer is indicated for each 
tumor cell (white numbers) and 
lymphocyte (yellow numbers)
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Statistical analysis
Statistical analysis was performed using JMP® 10 soft-
ware (SAS institute Inc., Cary, NC). Student’s t test was 
used to analyze continuous variables, and the χ2 test was 
used to analyze categorical variables. Cumulative sur-
vival rates were calculated by the Kaplan–Meier method. 
Significant differences in survival status were evaluated 
using the log-rank test. The Cox proportional hazards 
model was used in the multivariate analysis, and values 
are expressed using the hazard ratio (HR) with a 95% 




The patient background and clinico-pathological param-
eters are shown in Table 1. Of the 42 patients in the study, 
16 were women and 26 were men, with a median age 
at the time of diagnosis of 65s (range 50–83) years. In 
terms of TMN stage at diagnosis, three, six, 33, and zero 
patients were diagnosed at the T1, T2, T3, and T4 stages, 
respectively. Lymph node metastases were detected in 26 
of the patients (61.9%). Seven patients were identified 
as category M1 because of metastasis of the number 16 
lymph node without other organ metastasis. In terms of 
the pathological stage (pStage), as defined in the Union 
for International Cancer Control classification, three, 
four, nine, 19, and seven cases were at pStage Ia, Ib, 
IIa, IIb, and IV, respectively. The median survival time 
(MST) of the 42 patients was 26 months (Fig. 3).
Of the 42 patients, 27 (64.3%) underwent pathological 
curative resection, eight (19.0%) received neo-adjuvant 
chemo-radiation therapy, and 23 (54.8%) received adjuvant 
chemotherapy.
PD‑L1 expression in the 42 PDAC patients by DAB 
and PID staining
To judge the rate of positive PID staining, we first estab-
lished the threshold of the PID staining value. The average 
of the highest value of the negative control of PID staining 
was 3.01; therefore, the threshold value for judging posi-
tive PID staining was set to 3.0. Using this threshold, we 
detected PD-L1 expression in 26 of the 42 patients (61.9%).
By contrast, PD-L1 expression measured by the DAB-
naked eye evaluation was detected in only six of the 42 
patients (14.3%). This expression rate was measured to be 
between the PID positive staining value derived from the 
threshold set at 4.0 (28.6%, 12/42 patients) and 5.0 (11.9%, 
5/42 patients).
Relationship between PD‑L1 expression 
and clinico‑pathological features
The correlations between pathological features and PD-L1 
expression are shown in Table 2.
The ratio of males was significantly higher in the PD-
L1-positive group (male/female 20/6) than in the PD-
L1-negative group (male/female: 6/10 (P = 0.021). There 
was no significant correlation between PD-L1 expression 
Table 1  Patient characteristics and clinico-pathological data
The data in table are expressed as the median with the range in paren-
thesis or as the number of patients
Ph Pancreatic head, Pbt pancreatic body or tail
a R0 corresponds to curative resection or complete remission; R1 
corresponds to microscopic residual tumor
b T and N stage were based on the TNM classification of malignant 
tumors, sixth edition
c All M1 cases had No.16 lymph node metastasis without other organ 
metastasis
Patient characteristics Values (n = 42 patients)
Age (years) 65 (50–83)
Male/female 26/16
Tumor location (Ph/Pbt) 31/11
R0/R1a 27/15
Neo-adjuvant therapy (+/−) 8/34
Adjuvant therapy (+/−) 23/19
Pre-operative tumor marker CA19-9 134.2 (1.6–8116)
T stage (½/3)b 3/6/33
N stage (0/1)b 16/26
M stage (0/1)c 35/7
Tumor diameter (mm) 30 (16–75)
Fig. 3  Overall survival of 42 patients with pancreatic ductal adeno-
carcinoma (PDAC)
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and tumor size, lymph node metastasis [including dis-
tant lymph node metastasis (M1)], pre-operative tumor 
marker CA19-9 level, and R0/R1 (microscopic residual 
tumor) status. CD8+ TIL counts were not significantly 
correlated to PD-L1 expression.
Survival analysis
Survival curves obtained using the Kaplan–Meier method 
are shown in Fig. 4. Among the 42 patients, there was a 
significant difference in the overall survival rate between 
patients with PD-L1-positive disease and those with PD-
L1-negative disease based on PID staining (Fig. 4a. HR 
2.07, 95% CI 1.00–4.54; P = 0.049). The MST was 23.5 
months in the PD-L1-positive group and 51.6 months 
in the PDL-1-negative group. Among the 29 patients 
who had positive CD8+ TILs (>3 cells per 400× field), 
those in the PD-L1-positive group showed a significantly 
poorer overall survival rate than those in the PD-L1-neg-
ative group based on detection with the PID method 
(Fig. 4b. HR 3.84, 95% CI 1.59–10.35; P = 0.003).
The results of the univariate and multivariate analy-
ses in the 42 patients are shown in Table 3. Univariate 
and multivariate analyses revealed that PD-L1 expression 
determined by the PID method (PID staining value >3.0) 
was an independent prognostic factor (HR 2.34, 95% CI 
1.02–5.74; P = 0.045); specifically, in the 29 TIL-positive 
patients, PD-L1 expression determined by the PID method 
was an independent predictive poor prognostic factor 
(Table 4). Moreover, there was a stronger prognostic effect 
of PD-L1 expression among these 29 TIL-positive cases 
compared to the analysis including all 42 patients (HR 
4.39, 95% CI 1.64–13.34; P = 0.003).
Discussion
We report here the results of our investigation on PD-L1 
expression in patients with PDAC. The PD-L1-positive 
detection rate in PID staining was higher than that in DAB 
staining, possibly due to the fact that digital immunostain-
ing can detect proteins at lower concentrations. The higher 
fluorescence intensity of the nanoparticles contributes to 
the higher sensitivity of PID compared to DAB. In addition, 
quantitative analysis was possible even in cells with strong 
positive expression, without saturation.
In this study, the PD-L1 positive expression rate 
detected using the PID method in PDAC cases was higher 
than that reported in previous studies (4–49%) [15–17] 
using the DAB method. Among the cases in our study, 
no case was found to be negative for PID and positive 
for DAB. The PD-L1 positive expression rate was 14.3% 
using the DAB method and 61.9% using the PID method 
when the PID staining threshold value was set to 3.0. This 
result supported the current PD-L1 protein expression data 
using PID, which was found to be more sensitive than 
DAB. However, the DAB positive staining rate was similar 
to the PID positive staining rate when the threshold was 
set to 4.0 or 5.0; in other words, cells with slightly positive 
Table 2  Relationships between programmed death ligand 1 expression and pathological features
The data in table are expressed as the median with the range in parenthesis or as the number of patients
PD-L1 Programmed death ligand 1
a See footnotes to Table 1 for explanations of staging
Parametera PD-L1 expression (+) (n = 26) PD-L1 expression (−) (n = 16) P
Age (years) 64 (51–82) 66 (50–78) 0.385
Male/female 20/6 6/10 0.021
Tumor location (Ph/Pbt) 19/7 12/4 0.891
R0/R1 15/11 12/4 0.256
Neo-adjuvant therapy (+/−) 5/21 3/13 0.969
Adjuvant therapy (+/−) 15/11 8/8 0.627
Pre-operative tumor marker CA19-9 143.0 (1.6–8116) 113.0 (20.3–1712) 0.421
T stage (1, 2/3) 5/21 4/12 0.711
N stage (0/1) 10/16 6/10 0.950
M stage (0/1) 21/5 14/2 0.570
Tumor diameter (mm) 29.5 (18–75) 32.5 (16–45) 0.583
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expression showing three to five PID particles could not be 
detected by conventional methods.
Immunotherapeutic approaches, most notably immune 
checkpoint inhibitors epitomized by antibodies directed 
against T-lymphocyte regulators, cytotoxic T-lympho-
cyte-associated protein 4 (CTLA-4), and PD-1, have dem-
onstrated efficacy in a variety of solid tumors, including 
metastatic melanoma and lung cancer, and have already 
received U.S. Food and Drug Administration approval. 
PD-1/PD-Ll pathway blockade has resulted in significant 
and durable clinical responses in patients with several 
malignancies, such as melanoma, renal cell carcinoma, 
lung cancer, mismatch repair-deficient colorectal cancer, 
and bladder cancer [18]. However, PDAC has generally 
been considered to be a non-immunogenic malignancy, 
given that tumor-infiltrating effector T lymphocytes do 
not represent a histopathological hallmark of this disease 
[19, 20]. Investigators have been actively exploring the 
mechanisms underlying the evasion of immune surveil-
lance by pancreatic cancer cells, and several potential 
strategies have been proposed to overcome resistance to 
immune checkpoint inhibitors. In this study, TILs reached 
tumor cells in 29 of 42 surgical PDAC specimens.
In a clinical setting, patients with positive PD-L1 expres-
sion tend to show significantly unfavorable outcomes. Pre-
vious studies using DAB methods have also demonstrated 
that patients with PD-L1-positive PDAC showed unfavora-
ble outcomes. Wang et al. reported a correlation between 
B7-H1 (PD-L1) expression and pathological grade and 
TNM stage [16]. Nomi et al. reported that PD-L1-positive 
PDAC patients had a significantly poorer prognosis than 
PD-L1-negative patients [17]. Their data were similar to 
our results in that they found was no significant correla-
tion between tumor PD-L1 status and clinical indicators, 
including tumor status, nodal status, metastatic status, and 
pathological stage. In the current study, among the TIL-
positive patients there was PD-L1 expression which showed 
a stronger prognostic correlation than that observed in the 
analysis including all patients. Univariate and multivariate 
analyses showed that positive PD-L1 expression (PID stain-
ing value >3.0) was indeed an independent poor prognos-
tic factor in PDAC patients with positive CD8+ TILs. This 
result suggests that an immunosuppressive tumor microen-
vironment with high PD-L1 expression can interfere with 
the attack by TILs on the tumor cells. In these cases, there 
is a possibility that blockage of the PD-1/PD-L1 signaling 
pathway can result in the attack of TILs being dramati-
cally more effective. Although there have been no objective 
responses observed in patients with PDAC who received 
anti-PD-L1 antibody therapy [21], our results suggest that 
PD-L1-positive patients with TILs may be good candidates 
for anti-PD-L1 antibody therapy.
Conclusions
Phosphor-integrated dot staining provided superior 
results compared to those obtained by the canonical DAB 
staining method. We have shown for the first time that 
PD-L1, detected using PID staining, is a novel prognos-
tic marker for human PDAC. Digital immunostaining is 
Fig. 4  a Overall survival rates of 42 patients with PDAC corre-
lated to PD-L1 expression. Overall survival in patients with PD-
L1-positive disease was significantly poorer than that in patients 
with PD-L1-negative disease (P = 0.049). b Overall survival rate of 
29 patients showing positive CD8+ tumor-infiltrating lymphocytes 
(TILs) correlated to PD-L1 expression; there was a significant dif-
ference in prognosis between patients with PD-L1-positive and PD-
L1-negative disease (P = 0.003). HR Hazard ratio, CI confidence 
interval
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a promising tool for companion diagnostics to evaluate 
the therapeutic effects of molecular-targeted drugs and 
immunotherapy.
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